1 suspended. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Suspended 1 |
Follow Dyslipidemias: new trials by email Literature Review of Dyslipidemias trials Research Report on Dyslipidemias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Saroglitazar Magnesium 4 mg - Dyslipidemias | Phase 2 | Suspended | Zydus Therapeutics Inc. | 124 | 2017-04-06 | 2023-02-08 |
Hypertriglyceridemia (1) · Lipid Metabolism Disorders (1)
Hyperlipidemias (1) · Metabolic Diseases (1) · Nutritional and Metabolic Diseases (1)
saroglitazar (1)
United States (1)